BioPharma Dive April 23, 2024
The Swiss pharmaceutical giant now expects net sales to grow by high single to low double digits after what one analyst called an “impressive start” to the year.
Sales of Novartis drugs for heart failure, psoriasis and multiple sclerosis were stronger over the first three months of the year than anticipated, helping the Swiss pharmaceutical company report first quarter earnings Tuesday that beat Wall Street forecasts.
The drugmaker also raised its sales guidance for the year and now expects growth of high single to low double digits. Shares rose by as much as 4.5% in Tuesday morning trading on the New York Stock Exchange.
Novartis’ top-selling drugs Entresto and Cosentyx drove the beat, combining to bring in more than $3.2...
Today's Sponsors
Today's Sponsor